Prenetics Launches Major Warrant Exchange to Cut Dilution and Simplify Capital Structure

Claim 70% Off TipRanks This Holiday SeasonUnlock hedge-fund level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialPrenetics Group ( (PRE) ) just unveiled an update. On December 23, 2025, Prenetics Global Limited announced that it had entered into warrant exchange agreements with holders representing about 83.4% of its outstanding Class A and Class B warrants issued in an October 2025 financing. Under the voluntary program, investors exchanged one Class A and one Class B warrant—previously exercisable at $24.12 and $32.16, respectively, with five-year terms—for a single new Class C warrant exercisable at $18.00 per share for two years once a resale registration statement on Form F-3 becomes effective, and subject to a forced-redemption feature if the stock trades at or above $21.60 for ten consecutive trading days. The transaction, supported by several of Prenetics’ largest institutional shareholders, is expected to swap roughly 4.54 million legacy warrants for about 2.27 million Class C warrants, cutting the total warrant overhang to around 3.18 million instruments—about a 42% reduction from the October issuance, and up to 50% if all holders ultimately participate. Management says the move simplifies the capital structure, materially improves the company’s long-term dilution profile, and enhances the investability of its ordinary shares, while emphasizing that the exchange is not tied to any new financing and that Prenetics has no near-term plans for additional equity or equity-linked capital raising. The most recent analyst rating on (PRE) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page. Spark’s Take on PRE Stock According to Spark, TipRanks’ AI Analyst, PRE is a Neutral. The overall stock score of 51 reflects significant profitability challenges and valuation concerns, despite positive technical trends. The company’s strong equity base and low leverage provide some financial stability, but improvements in cash flow and profitability are essential for a more favorable outlook. To see Spark’s full report on PRE stock, click here. More about Prenetics Group Prenetics Global Limited (Nasdaq: PRE) is a health sciences company focused on consumer health and longevity, primarily through its flagship premium nutrition brand IM8. Co-founded with David Beckham and backed by a team of scientists, IM8 offers science-based supplement products such as its Daily Ultimate Essentials all-in-one powder, and has rapidly scaled to more than $100 million in annual recurring revenue within 11 months of launch, targeting the high-growth, premium wellness segment. Average Trading Volume: 157,927 Technical Sentiment Signal: Hold Current Market Cap: $246.6M For an in-depth examination of PRE stock, go to TipRanks’ Overview page.